¡Nuevo! Updated Spanish-Language Scleroderma Brochures

We recently revised several of our Spanish-language brochures. You can view some of our most popular brochure content, such as:

• Esclerodermia: Información General y Causas (Scleroderma: General Information and Causes)

• Esclerosis Sistémica: Difusa y Limitada (Systemic Scleroderma: Diffuse and Limited)

• Esclerodermia Localizada (Localized Scleroderma)

• La Hipertensión Pulmunar en la Esclerodermia (Pulmonary Hypertension in Scleroderma)

About ANA and Antibody Testing

An ANA test can detect antinuclear antibodies (ANA) in your blood. Your immune system normally makes antibodies to fight an infection. However, some people also create antinuclear antibodies, which often times can attack your body's own tissues.

Your doctor may say you need an ANA test to determine if you have an autoimmune disease, such as lupus, scleroderma or rheumatoid arthritis.

For more information, please visit sclerodermainfo.org >>

Video: Scleroderma Hands and Their Care

In this session from the 2015 National Patient Education Conference in Nashville, Dr. Francesco Boin discusses what’s causing damage and how to take good care of your hands.

View the entire session now >>

Prescription Drug User Fee Act (PDUFA) Reauthorization Process

The Prescription Drug User Fee Act (PDUFA) authorizes the U.S. Food and Drug Administration (FDA) to collect fees from pharmaceutical companies to help fund the agency’s drug review work. PDUFA’s intent is to provide additional funding for FDA to hire staff, improve systems, and establish a better-managed review process that enables us to do more timely reviews of human drug applications.

As a result, many important new drug therapies have been made available to patients sooner without compromising FDA’s high standards for safety, efficacy, and quality.

Learn more about PDUFA from the FDA Blog >>